Secondary amyloidosis screening

Revision as of 02:21, 30 October 2019 by Sahar Memar Montazerin (talk | contribs) (Created page with "__NOTOC__ {{Secondary amyloidosis}} {{CMG}} {{AE}} {{SHH}} ==Overview== There is insufficient evidence to recommend routine screening for amyloidosis...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Secondary amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Secondary amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Secondary amyloidosis screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Secondary amyloidosis screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Secondary amyloidosis screening

CDC on Secondary amyloidosis screening

Secondary amyloidosis screening in the news

Blogs on Secondary amyloidosis screening

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Secondary amyloidosis screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]

Overview

There is insufficient evidence to recommend routine screening for amyloidosis.

Screening

There is insufficient evidence to recommend routine screening for amyloidosis.

References

Template:WS Template:WH